Phase i study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: Blockade of the immune checkpoint CD200

Daruka Mahadevan, Mark C. Lanasa, Charles Farber, Manjari Pandey, Maria Whelden, Susan J. Faas, Terrie Ulery, Anjli Kukreja, Lan Li, Camille L. Bedrosian, Xiaoping Zhang, Leonard T. Heffner

Producción científica: Articlerevisión exhaustiva

58 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Phase i study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: Blockade of the immune checkpoint CD200'. En conjunto forman una huella única.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science